Drug Information Association (DIA) Annual Meeting

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about keeping patients informed at the 2023 DIA annual meeting in Boston, MA.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Venkatraman Balasubramanian, SVP and global head, industry solutions, healthcare and life sciences, Orion Innovation, provides a synopsis of "“The Case for Generating Synthetic Data as Real-World Data: Regulatory and Planning Perspectives.”

Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb speaks about giving patients more power in decision making at the 2023 DIA annual meeting in Boston, MA.

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

Panel explores challenges that could affect their development.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses issues that will be addressed at the upcoming FDA town hall.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses analyzing AI in Regulatory Decision Making

DIA session focuses on the ins and outs of returning individual participant data.

Session offers a look into the Inflation Reduction Act’s impact on market conditions.

Session explores practicality of models for selling low-cost drugs.

DIA session highlights strategies for stakeholders to make clinical trials more inclusive for diverse populations.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott, Senior Manager, Scientific Programs, Drug Information Association, discusses DIA educational opportunities improving clinical operations staff on DE&I concerns.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Tamei Elliott,Senior Manager, Scientific Programs, Drug Information Association, discusses changes to the role of diversity in clinical trials in regard to scientific programing.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses the near-term and long-term future of SMART on FHIR.

Panel at DIA discussed the evolving role of pharmacies in clinical trials.

In an interview at the DIA Global Annual Meeting with Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses his passion for SMART on FHIR.

Sponsors offers patient and caregiver insights on hybrid and decentralized clinical trial design provided by their feedback processes.

Integrated eCOA & ePRO solution taps company’s technology expertise.

Speakers dive into the importance of risk-based methods and central-monitoring solutions as they pertain to these trials.

DIA session offers an overview of the current regulatory landscape and challenges for both sponsors and regulators in achieving quality and integrity in the fast-moving area.

DIA President and Global Chief Executive provides the highlights for this year’s meeting being held in Boston at the end of June.